{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T10:08:35Z","timestamp":1778407715829,"version":"3.51.4"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Paragon Therapeutics"},{"DOI":"10.13039\/100032838","name":"Spyre Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032838","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/19420862.2026.2670848","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T09:27:13Z","timestamp":1778405233000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety"],"prefix":"10.1080","volume":"18","author":[{"given":"Matthew","family":"Siegel","sequence":"first","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Zhu","sequence":"additional","affiliation":[{"name":"Paragon Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rios","sequence":"additional","affiliation":[{"name":"Paragon Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byong H.","family":"Kang","sequence":"additional","affiliation":[{"name":"Paragon Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"McNally","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinjal","family":"Hew","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeyam","family":"Patel","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Ballew","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Giles","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M. A.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"LaFountaine","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Oh","sequence":"additional","affiliation":[{"name":"Paragon Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua R.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Rose","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Paragon Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Spyre Therapeutics","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19290-3"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178722"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01952-8"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2012.124"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891328"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700891"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.20"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00283-2"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231236"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635921"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(01)00215-1"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.09.097"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao4910"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2074401"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.03.002"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6917334\/v1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx328"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.04.23296543"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.09.184"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61983"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01335-1"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.078"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwad032"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00071-8"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00129-3"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314076"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0039B"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14187"},{"key":"e_1_3_5_32_1","volume-title":"M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals","author":"Harmonisation ICf","year":"2009","unstructured":"Harmonisation ICf. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Geneva, Switzerland: ICH; 2009."},{"key":"e_1_3_5_33_1","volume-title":"S6(R1) preclinical safety evaluation of biotechnology-derived pharmaceuticals","author":"Harmonisation ICf","year":"2011","unstructured":"Harmonisation ICf. S6(R1) preclinical safety evaluation of biotechnology-derived pharmaceuticals. Geneva, Switzerland: ICH; 2011."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301475"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02198-9"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802999"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24984-y"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01285-13"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"issue":"79","key":"e_1_3_5_40_1","article-title":"Interim phase 1 results for SPY002, a novel half-life extended monoclonal antibody targeting TL1A, suggest a potential for Q3M or Q6M maintenance dosing for rheumatologic disease","volume":"77","author":"Friedman J","year":"2025","unstructured":"Friedman J, Lu JD, Wang B, Hew K, Patel P, Kennedy M, Rose M, Sheldon C, McLean R, Svejnoha E, et al. Interim phase 1 results for SPY002, a novel half-life extended monoclonal antibody targeting TL1A, suggest a potential for Q3M or Q6M maintenance dosing for rheumatologic disease. Arthritis Rheumatol. 2025;77(suppl 79). https:\/\/acrabstracts.org\/abstract\/interim-phase-1-results-for-spy002-a-novel-half-life-extended-monoclonal-antibody-targeting-tl1a-suggest-a-potential-for-q3m-or-q6m-maintenance-dosing-for-rheumatologic-disease\/.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70035"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2026.2670848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T09:27:14Z","timestamp":1778405234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2026.2670848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/19420862.2026.2670848"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2026.2670848","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2670848"}}